DMPK
From early screening to IND-enabling studies, we deliver reliable data that meets global regulatory standards.
In Vitro ADME
Physicochemical Properties
- Kinetic solubility (buffers, dose vehicles, FASSIF, FESSIF, FASSGF)
- Thermodynamic solubility
- Chemical stability (buffers, dose vehicles, FASSIF, FESSIF, FASSGF)
Permeability Measurement
- Caco-2 cells
- MDCKII-MDR1 cells
Efflux and Uptake Transporters (substrate and inhibitor evaluation)
- P-gp/Caco-2 cells
- BCRP/Caco-2 cells
- P-gp/MDCKII-MDR1 cells
- OATP1B1, OATP1B3, OAT1, OAT3, OCT2, MATE1, MATE2K/HEK293T cells
Distribution (multiple species)
- Plasma protein binding
- Tissue protein binding
- Blood to plasma ratio (Cb/Cp)
- Red blood cell to plasma partition (CRBC/Cp)
Metabolic Stability (multiple species)
- Liver microsomal stability
- Hepatocyte stability
- Tissue homogenate stability (kidney, liver)
- Liver S9 fraction stability
- Liver lysosomal stability
- Intestine microsomal
- Liver S9 stability
- Plasma stability
- Blood stability
CYP450 Mediated Drug-Drug Interactions
- CYP450 inhibition (inhibition% or IC50)
- CYP450 time dependent inhibition (inhibition% or IC50 shift)
Metabolite Identification
- Metabolite identification in in vitro metabolic reaction systems, and in plasma and other fluids or tissues from PK or TK studies across different species
- Reactive metabolite GSH trapping
CYP450 Reaction Phenotyping
- CYP450 reaction phenotyping (rhCYP and chemical inhibition)
In Vitro ADME Study Capacity:
>100 cpds/month for >30 ADME assays
Turnaround Time:
5 working days for regular enzyme-based assays
10 working days for cell-based and metabolite identification assays
Reprogramming Cells, Empowering Medicine
©2026 PRECEDO Biotechnology Co., Ltd. Powered by：www.300.cn